Den Europæiske Union - dansk - EMA (European Medicines Agency)

novartis europharm limited - trametinib - melanom - antineoplastiske midler - melanomatrametinib as monotherapy or in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation (see sections 4. 4 og 5. trametinib monotherapy has not demonstrated clinical activity in patients who have progressed on a prior braf inhibitor therapy (see section 5. adjuvant treatment of melanomatrametinib in combination with dabrafenib is indicated for the adjuvant treatment of adult patients with stage iii melanoma with a braf v600 mutation, following complete resection. ikke-småcellet lungekræft (nsclc)trametinib i kombination med dabrafenib er indiceret til behandling af voksne patienter med avanceret ikke-småcellet lungekræft med en braf v600 mutation.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

novartis europharm limited - dabrafenib mesilate - melanom - antineoplastiske midler - melanomadabrafenib as monotherapy or in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation (see sections 4. 4 og 5. adjuverende behandling af melanomadabrafenib i kombination med trametinib er angivet for den adjuverende behandling af voksne patienter med stadium iii melanom med en braf v600 mutation, efter komplet resektion. non-small cell lung cancer (nsclc)dabrafenib in combination with trametinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a braf v600 mutation.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

hexal a/s - dimethylfumarat - enterokapsler, hårde - 120 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

hexal a/s - dimethylfumarat - enterokapsler, hårde - 240 mg

Den Europæiske Union - dansk - EMA (European Medicines Agency)

roche registration gmbh  - pralsetinib - carcinom, ikke-småcellet lunge - antineoplastiske midler - gavreto is indicated as monotherapy for the treatment of adult patients with rearranged during transfection (ret) fusion-positive advanced non-small cell lung cancer (nsclc) not previously treated with a ret inhibitor.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

krka, d.d. - memantinhydrochlorid - alzheimers sygdom - andre anti-demensmidler - behandling af patienter med moderat til svær alzheimers sygdom.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

actavis group ptc ehf. - memantin - alzheimers sygdom - psychoanaleptics, , andre demensmedicin - behandling af patienter med moderat til svær alzheimers sygdom.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

krka d.d. novo mesto - memantinhydrochlorid - filmovertrukne tabletter - 10 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

krka d.d. novo mesto - memantinhydrochlorid - filmovertrukne tabletter - 20 mg

Den Europæiske Union - dansk - EMA (European Medicines Agency)

heron therapeutics, b.v. - bupivacaine, meloxicam - smerte, postoperative - anæstesiologi - zynrelef is indicated for treatment of somatic postoperative pain from small- to medium-sized surgical wounds in adults (see section 5.